<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of alpha-1 antitrypsin deficiency</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of alpha-1 antitrypsin deficiency</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of alpha-1 antitrypsin deficiency</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James K Stoller, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Severe deficiency of alpha-1 antitrypsin (AAT) is associated with early onset pulmonary emphysema and with several forms of liver disease, including cirrhosis, neonatal hepatitis, and hepatocellular carcinoma.</p><p>The discovery of the structure and function of the AAT protein, and its subsequent isolation and purification, have allowed augmentation therapy (so-called because of less than total replacement) aimed at preventing progression of emphysema [<a href="#rid1">1,2</a>]. The goal of most specific treatment approaches for AAT deficiency is to raise the serum AAT level (and therefore the concentration of AAT in the lung interstitium) above the "protective threshold." Organ transplantation is another option for patients with end-stage lung or liver disease.</p><p>The treatment of AAT deficiency will be reviewed here. The clinical manifestations, genetics, and diagnosis of AAT deficiency are discussed separately. (See  <a class="medical medical_review" href="/d/html/1464.html" rel="external">"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency"</a> and  <a class="medical medical_review" href="/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency"</a>.)</p><p class="headingAnchor" id="H1644082995"><span class="h1">SUPPORTIVE CARE AND STANDARD MEDICAL THERAPY</span><span class="headingEndMark"> — </span>Supportive care and standard medical therapy for patients with AAT deficiency follow the guidelines for the management of chronic obstructive pulmonary disease (COPD) [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a>.)</p><p>The following components should be included  (<a class="graphic graphic_table graphicRef52673" href="/d/graphic/52673.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Cigarette smoking is known to accelerate progression of lung disease in AAT deficiency. Patients with genetic variants of AAT associated with lung disease should avoid active and passive exposure to cigarette smoke [<a href="#rid3">3,4</a>]. (See  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical therapy with bronchodilators (such as beta agonists and muscarinic antagonists) and inhaled or oral glucocorticoids should follow guidelines for COPD [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary rehabilitation is appropriate for patients with decreased exercise tolerance. (See  <a class="medical medical_review" href="/d/html/1463.html" rel="external">"Pulmonary rehabilitation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nutritional support should be provided as appropriate to maintain a healthy body weight. (See  <a class="medical medical_review" href="/d/html/1440.html" rel="external">"Malnutrition in advanced lung disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be assessed for resting hypoxemia and supplemental oxygen prescribed if the pulse oxygen saturation (SpO<sub>2</sub>) is 88 percent or lower at rest. Preliminary evidence suggests that patients with AAT deficiency may have more severe desaturation on ambulation than AAT-sufficient patients with COPD [<a href="#rid5">5</a>]. Thus, assessment of oxygenation during exertion (eg, during a six-minute walk test) may be appropriate. (See  <a class="medical medical_review" href="/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prompt treatment of lower respiratory tract infections (eg, influenza, bacterial bronchitis, flares of bronchiectasis, pneumonia) to minimize the inflammatory cell burden in the lung.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preventive vaccination (eg, influenza and pneumococcal vaccines). (See  <a class="medical medical_review" href="/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a> and  <a class="medical medical_review" href="/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">INTRAVENOUS AUGMENTATION THERAPY</span><span class="headingEndMark"> — </span>Intravenous augmentation via the infusion of pooled human <a class="drug drug_general" data-topicid="8495" href="/d/drug information/8495.html" rel="external">alpha-1 proteinase inhibitor</a> (alpha-1 antitrypsin, AAT) is currently the most direct and efficient means of elevating AAT levels in the blood and lung interstitium [<a href="#rid6">6,7</a>]. The goal of AAT augmentation is to slow the progression of emphysema.</p><p class="headingAnchor" id="H3522025352"><span class="h2">Patient selection</span><span class="headingEndMark"> — </span>Recommendations from official organizations regarding the specific indications for pooled human AAT augmentation vary [<a href="#rid3">3,8,9</a>]. We suggest augmentation for never or ex-smokers age 18 or older with an AAT genetic variant consistent with severe AAT deficiency, a low serum level of AAT (ie, &lt;11 micromol/L or &lt;57 mg/dL), and evidence of airflow limitation  (<a class="graphic graphic_algorithm graphicRef112788" href="/d/graphic/112788.html" rel="external">algorithm 1</a>). Treatment decisions may benefit from consultation with a referral center with expertise in AAT deficiency.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum AAT level</strong> – Most patients with PI*ZZ (protease inhibitor Z) or PI*Null genetic variants have a serum AAT level &lt;11 micromol/L (enzyme-linked immunosorbent assay) or &lt;57 mg/dL (nephelometry)  (<a class="graphic graphic_table graphicRef57264" href="/d/graphic/57264.html" rel="external">table 2</a>). For other genetic variants, the same range of serum levels (&lt;11 micromol/L or &lt;57 mg/dL) is considered the minimum "protective threshold," and these serum levels should be used as a general guide for considering augmentation therapy [<a href="#rid4">4</a>]. Individuals with rare genetic variants like the PI*FF genotype may have relatively normal serum levels of AAT but a dysfunctional AAT protein that poses risk for emphysema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity of airflow limitation</strong> – The Global Initiative for Chronic Obstructive Pulmonary Disease guidelines suggest that the most suitable patients for augmentation have severe AAT deficiency and an forced expiratory volume in one second (FEV<sub>1</sub>) of 35 to 65 percent of predicted [<a href="#rid3">3</a>]. The rationale for selecting this range of FEV<sub>1</sub> is that AAT deficient patients with a higher FEV<sub>1</sub> may not develop clinically evident emphysema. The American Thoracic Society suggests weekly augmentation therapy with human pooled AAT for individuals who have serum levels of AAT less than 11 micromol/L and established airflow obstruction, defined as an FEV<sub>1</sub> &lt;80 percent predicted [<a href="#rid8">8</a>]. In comparison, the Canadian Thoracic Society suggests reserving AAT augmentation therapy for AAT-deficient patients (AAT level less than 11 micromol/L) with an FEV<sub>1</sub> of 25 to 80 percent predicted who have quit smoking and are on optimal medical therapy [<a href="#rid9">9</a>]. Indications for use of AAT augmentation outside these thresholds for airflow limitation have not been uniformly agreed upon [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1">In our practice, if the FEV<sub>1</sub> is &gt;65 percent of predicted, but declines by ≥100 mL/year in an AAT deficient patient, we initiate augmentation therapy. </p><p></p><p class="bulletIndent1">A lower limit of FEV<sub>1</sub> below which augmentation therapy should be withheld has not been determined, although available studies do not demonstrate clinical efficacy as measured by FEV<sub>1</sub> in patients with severe airflow obstruction (eg, FEV<sub>1</sub> &lt;35 percent predicted). Advocates suggest that defending against any decrement in lung function is important in these patients. On the other hand, opponents suggest that the efficacy of therapy in preventing loss of the little remaining FEV<sub>1</sub> is negligible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence of emphysema on HRCT</strong> – Though some disagree, guidelines suggest including chest computed tomography to identify emphysema as part of the initial assessment of the AAT deficient patient [<a href="#rid11">11</a>]. In clinical trials, sensitive measures of lung density by high resolution computed tomography (HRCT) have demonstrated a decreasing rate of loss of lung density over time in patients with severe AAT deficiency who receive augmentation therapy. In addition, some patients have HRCT evidence of emphysema without airflow limitation on spirometry. In the absence of data to support initiating AAT augmentation in this setting, our approach is to follow these patients closely (eg, every six months) with spirometry and diffusing capacity measurements in order to identify early or progressive declines in FEV<sub>1 </sub>(eg, ≥100 mL/year) or diffusing capacity (eg, &gt;15 percent decline), at which time augmentation therapy can be begun.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional selection criteria</strong> – Anticipated adherence to the protocol for weekly infusions may contribute to the decision about initiating augmentation. </p><p></p><p class="bulletIndent1">Guidelines suggest augmentation for patients with necrotizing panniculitis in association with AAT deficiency [<a href="#rid11">11</a>]. Panniculitis is an off-label indication for augmentation therapy. (See  <a class="medical medical_review" href="/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency"</a>.)</p><p></p><p>Augmentation therapy is <strong>not</strong> recommended for patients who are PI*MZ heterozygotes, whose serum AAT level almost invariably exceeds 11 micromol/L or 57 mg/dL [<a href="#rid12">12</a>] or those with emphysema in the absence of documented AAT deficiency. Heterozygous individuals with the PI*MZ, PI*SZ, or PI*MS genetic variants are generally not candidates for AAT augmentation, as they are not at increased risk for panacinar emphysema in the absence of smoking.</p><p class="headingAnchor" id="H3016556027"><span class="h2">Pretreatment preparation</span><span class="headingEndMark"> — </span>For patients who meet criteria for AAT augmentation, we obtain a baseline serum IgA level (as all commercial preparations of AAT augmentation therapy contain some IgA and patients with severe deficiency of IgA are at risk of anaphylaxis with infusion of pooled human AAT). We also obtain baseline spirometry and diffusion capacity for carbon monoxide (within a year of initiation). </p><p>Selective immunoglobulin A (IgA) deficiency (&lt;7 mg/dL) affects approximately 0.1 to 1 percent of the population. A minority of patients with undetectable IgA in serum form antibodies to IgA that can be associated with systemic reactions to pooled human plasma containing IgA. We avoid AAT augmentation in these patients, due to concerns about anaphylaxis. Consultation with an allergy/immunology specialist and measurement of a serum antibodies to IgA can help define the risk of anaphylaxis due to IgA sensitivity in individual patients. (See  <a class="medical medical_review" href="/d/html/3936.html" rel="external">"Selective IgA deficiency: Management and prognosis", section on 'Reactions to blood products'</a>.) </p><p>Vaccination against hepatitis A and B for those who are not already immune can help prevent superimposed insults to the liver, but is not necessary prior to AAT augmentation therapy, due to the low risk of transmission. </p><p class="headingAnchor" id="H4055938319"><span class="h2">Formulations</span><span class="headingEndMark"> — </span>Four pooled human plasma AAT products are available, Aralast NP, Prolastin-C (also available as Prolastin C – Liquid), Zemaira, and Glassia. The first three are supplied in a powdered, lyophilized form and Glassia and Prolastin C - Liquid as liquid preparations. For the lyophilized preparations, the directions for reconstitution provided in the package insert should be followed closely. After reconstitution, pooled AAT should be used within three hours.</p><p class="headingAnchor" id="H5"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>The only US Food and Drug Administration (FDA)-approved regimen for AAT is 60 mg/kg body weight, given as weekly infusions. Studies have shown that weekly infusions of human pooled AAT at a dose of 60 mg/kg maintain AAT levels in serum and epithelial lining fluid above the protective threshold, both throughout the week and over the long-term  (<a class="graphic graphic_figure graphicRef68873" href="/d/graphic/68873.html" rel="external">figure 1</a>) [<a href="#rid1">1,2,13</a>]. Serum levels are more consistently above the protective threshold with weekly than biweekly or monthly therapy, although differences in clinical outcomes have not been formally assessed. </p><p>Although effective, weekly infusions can be difficult for patients and support staff. To reduce the frequency of treatment, the efficacy of giving larger doses biweekly has been studied. In a series of 23 patients, simply doubling the dose of AAT to 120 mg/kg and administering every other week was not sufficient to maintain the serum level above the protective threshold through the entire dosing interval [<a href="#rid14">14</a>]. Pharmacokinetic modeling suggested that a dose of 200 mg/kg could be required for biweekly infusions [<a href="#rid14">14</a>]. </p><p>In comparison, monthly infusions of 250 mg/kg appear biochemically effective. In one small study (9 patients) with AAT deficiency (eight PI*ZZ and one PI*Z null), monthly infusions of human pooled AAT at a dose of 250 mg/kg (ie, four times the weekly infusion dose) effectively raised serum and epithelial lining fluid (ELF) AAT levels  (<a class="graphic graphic_figure graphicRef79807" href="/d/graphic/79807.html" rel="external">figure 2</a>), as well as anti-neutrophil elastase activity, above the protective thresholds [<a href="#rid15">15</a>]. This effect was maintained until the next dose and over the long-term. This study was subsequently extended as monthly infusions were given for up to 24 months in eight severely deficient patients [<a href="#rid2">2</a>]. Further study would be needed to determine the efficacy of monthly dosing.</p><p class="headingAnchor" id="H2193492131"><span class="h2">Infusion</span><span class="headingEndMark"> — </span>A protocol for intravenous AAT augmentation therapy is summarized in the table  (<a class="graphic graphic_table graphicRef52673" href="/d/graphic/52673.html" rel="external">table 1</a>). As noted above, weekly infusions of AAT 60 mg/kg actual body weight is the only FDA-approved regimen. (See <a class="local">'Dosing'</a> above.)</p><p>The infusion rate is typically 0.08 to 0.2 mL/kg body weight per minute, depending on the individual preparation, such that the average weekly infusion takes 15 minutes  (<a class="graphic graphic_table graphicRef52673" href="/d/graphic/52673.html" rel="external">table 1</a>). Emergency equipment (including <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>) should be immediately available during the infusion. The infusion rate may need to be reduced or interrupted if the patient develops an adverse event. </p><p class="headingAnchor" id="H2062586606"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>The guidelines for AAT augmentation do not advise routine monitoring of serum AAT levels during therapy [<a href="#rid11">11</a>]. Annual monitoring of spirometry, diffusing capacity, and ambulatory oximetry is advised. </p><p>Computed tomography (CT) densitometry is a more sensitive measure for assessing emphysema progression than spirometry; however, radiation exposure has generally discouraged the use of serial chest CT scans for routine monitoring in patients with AAT deficiency [<a href="#rid16">16</a>].</p><p>The role of annual low dose CT scans for lung cancer screening in high risk individuals (eg, ages 50 to 80 years with 20 pack-year history of smoking, and current smoker or quit within past 15 years) is discussed separately. (See  <a class="medical medical_review" href="/d/html/7566.html" rel="external">"Screening for lung cancer", section on 'Summary and recommendations'</a>.)</p><p>Some guidelines suggest that adults with AAT deficiency undergo annual monitoring for liver disease with measurement of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), albumin, bilirubin, prothrombin time/international normalized ratio (INR), and platelets [<a href="#rid11">11</a>]. Liver elastography to assess fibrosis is increasingly being used to monitor patients whose AAT genotype causes protein misfolding and intra-hepatic accumulation of unsecreted abnormal AAT. The most common such variant is PI*ZZ. (See  <a class="medical medical_review" href="/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency", section on 'Adult onset'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Infusion therapy with intravenous pooled human AAT appears to be safe, well tolerated, and without significant adverse effects [<a href="#rid17">17-21</a>]. Although all current AAT products are pooled human plasma derivatives, no cases of HIV or hepatitis transmission or of viral antibody development have been reported in recipients [<a href="#rid2">2,22</a>]. (See  <a class="medical medical_review" href="/d/html/7929.html" rel="external">"Pathogen inactivation of blood products"</a>.)</p><p>Investigators from the National Heart, Lung, and Blood Institute Registry of Patients with Severe Deficiency of Alpha-1 Antitrypsin reported their experience with adverse reactions to augmentation therapy [<a href="#rid23">23</a>]. The overall incidence of adverse events was 0.02 per patient-month of treatment. Most events were of moderate severity, and included dizziness, chest tightness, rash, hives, and fever. A small number of severe adverse effects, including wheeze, hypotension, and loss of consciousness were reported. Over 80 percent of patients involved in the survey reported no adverse events associated with treatment.</p><p>There are, however, some problems that can occur [<a href="#rid20">20,23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flu-like symptoms</strong> – Low-grade fever (1 to 5 percent) and mild flu-like symptoms are usually self-limited. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity</strong> – Anaphylaxis with IgE antibody formation to AAT has been reported, but is extremely rare (&lt;1 percent) [<a href="#rid24">24</a>]. Anaphylaxis may be due to antibodies to human alpha1-protease inhibitor or to IgA, if the patient is IgA deficient. Rash, urticaria, and angioedema are also reported, but uncommonly. (See <a class="local">'Pretreatment preparation'</a> above and  <a class="medical medical_review" href="/d/html/3963.html" rel="external">"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis", section on 'Anaphylactic reactions to blood products'</a> and  <a class="medical medical_review" href="/d/html/7947.html" rel="external">"Immunologic transfusion reactions", section on 'Anaphylactic transfusion reactions'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential volume overload</strong> – Pooled human AAT is a colloid solution and can transiently increase blood volume. Patients at risk for volume overload should be monitored during and after intravenous infusion. Sometimes the rate of infusion needs to be slowed, or diuretic agents administered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transmission of infectious agents</strong> – More than 20 years ago, several lots of the original Prolastin preparation were withdrawn from the market when it was discovered that some of the intermediates used to produce the drug derived from two individuals diagnosed with Creutzfeldt-Jakob disease (CJD) [<a href="#rid25">25</a>]. However, there have been no reports of human-to-human transmission of CJD through blood products, and there is no known association between blood transfusion and the development of CJD [<a href="#rid26">26-29</a>]. Thus, the risk to recipients is deemed very low. </p><p></p><p class="bulletIndent1">While the risk of transmission of human pathogenic agents cannot be entirely eliminated, all pooled human AAT products are serologically negative for HIV, hepatitis B, and hepatitis C [<a href="#rid26">26-29</a>]. Viral reduction and inactivation steps are followed to reduce the possibility of transmission of viruses, such as hepatitis A, Creutzfeldt-Jakob disease, and parvovirus. (See  <a class="medical medical_review" href="/d/html/5084.html" rel="external">"Creutzfeldt-Jakob disease"</a> and  <a class="medical medical_review" href="/d/html/7929.html" rel="external">"Pathogen inactivation of blood products"</a>.)</p><p></p><p class="headingAnchor" id="H1966233686"><span class="h2">Clinical efficacy</span><span class="headingEndMark"> — </span>Data in support of clinical efficacy of intravenous AAT are largely comprised of randomized trials that assessed outcomes such as serum AAT levels, lung function, and lung density on computed tomography [<a href="#rid17">17,21,22,30-32</a>]. Long-term clinical trial data on patient-important outcomes, such as frequency of exacerbations, quality of life, need for lung transplantation, and mortality, are more limited.</p><p></p><p>A systematic review and meta-analysis that included 1509 patients concluded that augmentation had a modest effect in slowing lung function decline [<a href="#rid31">31</a>]. The decline in FEV<sub>1</sub> was slower by 23 percent (absolute difference, 13.4 mL/year, 95% CI 1.5-25.3 mL/year) among all patients receiving augmentation therapy, compared with placebo. Patients with moderate airflow obstruction (FEV<sub>1</sub> from 30 to 65 percent predicted) appeared most likely to benefit. A Cochrane systematic review of three randomized trials (283 participants) that included the RAPID trial described below found that the rate of loss of CT density was significantly lower among augmentation therapy recipients, but that no effect was observed in exacerbations, quality of life, or rate of decline of FEV<sub>1</sub> [<a href="#rid33">33</a>]. </p><p>In the RAPID randomized trial, the rates of change of CT lung density were compared between 93 patients receiving weekly AAT augmentation therapy and 87 placebo recipients [<a href="#rid21">21</a>]. The rate of loss of lung density among augmentation therapy recipients tended to be lower on the coprimary endpoint of CT density assessed at functional residual capacity (FRC) and at total lung capacity (TLC) and achieved significance on the density measured at TLC. No differences were observed between the compared groups regarding change in FEV<sub>1</sub> or diffusing capacity for carbon monoxide (DLCO), scores on the St George's Respiratory Questionnaire, or exacerbation frequency.</p><p>In a follow-up study to the RAPID trial (called RAPID-OLE for "open label extension"), augmentation therapy was provided to 76 participants from the original augmentation therapy group (early start) and 64 participants from the placebo group (start of augmentation therapy delayed by two years) for an additional two years [<a href="#rid34">34</a>]. The rate of lung density loss was slower in the early start patients, compared with delayed start patients. The rate of decline in lung density manifest by the delayed start group decreased during RAPID-OLE compared with their rate of lung loss during the RAPID trial, but lost lung density was never recovered. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduction in exacerbations</strong> – Other studies have found that AAT augmentation is associated with fewer exacerbations of COPD [<a href="#rid35">35,36</a>]. In an observational study, the rate of exacerbations decreased from 3 to 5 infections/year before therapy to 0 to 1 infections/year after starting therapy [<a href="#rid35">35</a>]. While randomized trials of augmentation therapy have not shown an overall effect on exacerbation frequency, a post hoc analysis of a clinical trial reported a decrease in severity of exacerbations [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung function and survival in observational studies</strong> – The results of some observational studies of augmentation therapy not included in the Cochrane meta-analysis support a beneficial effect on survival and lung function [<a href="#rid32">32</a>] and strengthen support for the clinical efficacy of intravenous augmentation therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The National Registry of Patients with Severe Deficiency of Alpha-1 Antitrypsin conducted a multicenter, prospective, observational cohort study of 1129 patients and reported enhanced survival in recipients of augmentation therapy compared with non-recipients [<a href="#rid18">18,37</a>]. In the subset of patients with FEV<sub>1</sub> 35 to 49 percent predicted, the rate of FEV<sub>1</sub> decline was also slowed in recipients of augmentation therapy, though the observational nature of the study precludes certainty about the finding.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective observational study of 615 persons with severe AAT deficiency compared patients from Ireland, where augmentation was rarely available, with those from Switzerland and Austria, where it was supplied for those with moderately impaired or worsening lung function [<a href="#rid38">38</a>]. Despite a similar age distribution and fewer lung symptoms at baseline, Irish patients had increased mortality compared with those from the other two countries. AAT augmentation decreased mortality (HR 0.61, 95% CI 0.45-0.83) in the cohort but did not have a significant effect on FEV<sub>1</sub> decline.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A similar observational study compared the rate of FEV<sub>1</sub> decline among 97 Danish former smokers with severe AAT deficiency who did not receive augmentation therapy with that of 198 severely deficient German former smokers who received weekly infusions (60 mg/kg) over a mean of 3.2 years [<a href="#rid39">39</a>]. Overall, the rate of decline of FEV<sub>1</sub> was lower among the treated patients than among the untreated (-53 mL per year versus -75 mL per year, p = 0.02).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A longitudinal study following 96 patients with severe alpha-1 antitrypsin deficiency analyzed the rate of decline in FEV<sub>1 </sub>before and after initiation of weekly augmentation therapy [<a href="#rid40">40</a>]. In distinction to other observational studies discussed above, this study showed that the rate of decline in FEV<sub>1 </sub>during augmentation therapy was slowest in those patients with mild airflow obstruction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protective threshold</strong> – Achieving certain serum values does not necessarily correlate with protection against lung function decline. The protective threshold levels of AAT in serum and ELF reflect estimates of values that separate affected from unaffected individuals. Because a "true" protective threshold value is not available, the amount of augmentation needed to prevent or retard disease is not precisely known. As some severely deficient patients have normal lung function, it is apparent that serum levels and genotype alone do not predict disease, but only assign a risk for developing disease. Ideally, outcomes such as mortality, exacerbations, exercise tolerance, quality of life, and lung function would be used to assess efficacy. The slow rate of disease progression (in the absence of cigarette smoke exposure) and the need for a placebo group make it more difficult perform long-term studies with robust patient-important outcomes in an uncommon disease like AAT deficiency [<a href="#rid41">41</a>].</p><p></p><p class="headingAnchor" id="H1742665492"><span class="h2">Cost and availability</span><span class="headingEndMark"> — </span>High cost remains an issue for AAT augmentation, and all of the preparations available in the United States are costly (estimated &gt;$100,000/year). Due to the high cost, AAT augmentation is not available in many countries.</p><p class="headingAnchor" id="H14"><span class="h1">LUNG VOLUME REDUCTION SURGERY</span><span class="headingEndMark"> — </span>Lung volume reduction surgery (LVRS, also called reduction pneumoplasty or bilateral pneumectomy) is a surgical technique that entails reducing the lung volume by wedge excision of emphysematous tissue. Small studies of LVRS in AAT deficient patients suggest caution in advising LVRS for AAT deficient patients [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/1430.html" rel="external">"Lung volume reduction surgery in COPD"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In one trial, 10 AAT deficient patients who underwent LVRS had a higher two year mortality than similar patients randomly assigned to medical therapy [<a href="#rid42">42</a>]. In addition, AAT deficient patients had a smaller increase in exercise tolerance and a smaller and less sustained improvement in forced expiratory lung volume in one second (FEV<sub>1</sub>), compared with AAT nondeficient patients. Statistical analysis was limited due to the small sample size. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate study, 17 AAT deficient and 35 AAT nondeficient patients underwent unilateral LVRS [<a href="#rid43">43</a>]. When assessed at one year after surgery, the nondeficient group had sustained improvements in lung function, dyspnea score, and walking distance, while the deficient group had nonsustained or marginal improvement.</p><p></p><p>Basal predominance of emphysema or diffuse emphysema with a low diffusing capacity for carbon monoxide may make LVRS more difficult in AAT deficient patients [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H15"><span class="h1">LUNG AND LIVER TRANSPLANTATION</span><span class="headingEndMark"> — </span>Advances in solid organ transplantation have made lung and liver transplantation available as therapeutic options for AAT deficient patients. (See  <a class="medical medical_review" href="/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency", section on 'Hepatic disease'</a> and  <a class="medical medical_review" href="/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a> and  <a class="medical medical_review" href="/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection", section on 'Chronic obstructive pulmonary disease (COPD)'</a>.)</p><p>Liver transplantation is reserved for patients with end-stage hepatic disease. It has the additional advantage of correcting the AAT deficiency, because a normal (PI*MM) donor liver produces and secretes AAT, which appears to slow the rate of decline in lung function in some patients [<a href="#rid44">44-46</a>]. The AAT level should be assessed after liver transplant to ensure normalization. (See  <a class="medical medical_review" href="/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a>.)</p><p class="headingAnchor" id="H1435013159"><span class="h2">Selection of candidates for lung transplantation</span><span class="headingEndMark"> — </span>Selection of patients with AAT deficiency for lung transplant follows guidelines for other patients with advanced lung disease. (See  <a class="medical medical_review" href="/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection", section on 'Chronic obstructive pulmonary disease (COPD)'</a>.)</p><p>One important consideration for potential lung transplant candidates with AAT deficiency relates to the possibility of underlying liver disease. In a single institution study, a pretransplant liver biopsy was performed in all lung transplant candidates with Pi*ZZ emphysema [<a href="#rid47">47</a>]. Chronic liver disease was noted on biopsy in 20 of 23 patients and two patients met criteria for severe liver disease. The two patients with severe liver disease were asymptomatic and had normal liver function tests; one had an abnormal ultrasound. Seventeen patients underwent lung transplantation, and no evidence of decompensation of liver disease was noted; the two with severe liver disease were not listed for transplant. We assess liver function tests and elastography prior to listing a patient for lung transplantation, but do not routinely perform liver biopsy. (See  <a class="medical medical_review" href="/d/html/96717.html" rel="external">"Noninvasive assessment of hepatic fibrosis: Ultrasound-based elastography"</a>.)</p><p class="headingAnchor" id="H86799383"><span class="h2">Outcomes of lung transplantation</span><span class="headingEndMark"> — </span>Observational studies suggest that lung transplantation in patients with advanced lung disease due to AAT deficiency has a comparable survival to lung transplantation for AAT-nondeficient patients with chronic obstructive pulmonary disease (COPD) and improves survival compared with standard (nontransplant) care, as noted in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a single-center study, the outcomes of 45 patients who underwent lung transplantation for AAT deficiency were compared with those of 231 AAT-nondeficient patients who underwent lung transplantation for COPD [<a href="#rid48">48</a>]. AAT deficiency was not a risk factor for early or late post-transplant death. Single lung recipients in both groups experienced a similar rate of decline in the forced expiratory lung volume in one second (FEV<sub>1</sub>). However, among bilateral lung transplant recipients, the rate of decline in FEV<sub>1</sub> was greater in those who were AAT deficient compared with those who had normal levels of AAT. The cause of this discrepancy is unclear. No differences in the frequency or severity of acute cellular rejection episodes were observed.</p><p></p><p class="bulletIndent1">The effect of AAT augmentation on lung allograft function could not be assessed, as only six AAT-deficient patients received augmentation after transplantation. (See <a class="local">'Augmentation following lung transplantation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective case-control study, 83 patients with advanced emphysema due to AAT deficiency (PI*ZZ) underwent single (62) or bilateral (21) lung transplantation; survival was compared with 70 nontransplanted AAT deficient individuals of similar age, sex, smoking history and lung function [<a href="#rid49">49</a>]. The median survival times were significantly longer among transplanted (11 years, 95% CI 9-14) versus nontransplanted (5 years, 95% CI 4-6) patients. Given the study design, it is possible that unidentified factors contributed to early mortality among those who did not seek lung transplantation.</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Augmentation following lung transplantation</span><span class="headingEndMark"> — </span>Continuation of AAT augmentation therapy following lung transplantation is controversial, largely because it is costly [<a href="#rid16">16,50</a>]. Most transplant centers do not give augmentation therapy to AAT deficient lung transplant recipients, as it is not known whether it would improve outcomes or longevity during the patient's lifetime, and significant recurrent emphysema is unlikely to occur for 30 to 40 years in the absence of smoking [<a href="#rid48">48,51</a>].</p><p>In our practice, we observe lung function after transplant and initiate augmentation only if the patient has persistent lung function decline. This practice is supported by a report that two of four lung transplant recipients responded to weekly augmentation therapy after experiencing lung function decline refractory to the usual therapies for bronchiolitis obliterans syndrome [<a href="#rid52">52</a>]. Theoretically, AAT augmentation could also be initiated if characteristic radiologic changes of emphysema were to develop in the absence of lung function decline. </p><p>Other authors suggest providing once-weekly therapy (60 mg/kg) during conditions associated with an increased neutrophil burden in the lung (as with pneumonia or acute rejection), although data in support of this practice are lacking [<a href="#rid48">48,50,53</a>].</p><p class="headingAnchor" id="H1952820236"><span class="h1">EMERGING THERAPIES</span><span class="headingEndMark"> — </span>A number of emerging therapies that use novel treatment approaches for AATD are being investigated, though none is currently approved for use. These potential interventions include gene therapy, augmentation therapy using modified proteins that require less frequent infusion, corrector molecules that prevent misfolding and allow more normal secretion of AAT protein that might otherwise polymerize within the hepatocyte, and interfering mRNA that suppresses Z protein expression within the hepatocyte. Evolving study of these various approaches will clarify whether they have efficacy and will receive regulatory approval for use. (See  <a class="medical medical_review" href="/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing"</a>.)</p><p class="headingAnchor" id="H86799430"><span class="h1">ADDITIONAL RESOURCES</span><span class="headingEndMark"> — </span>The Alpha-1 Foundation in the United States provides information for patients and their caregivers and also maintains a registry and an AAT deficiency specific genetic counseling program (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Falpha1.org%2F&amp;token=PYblK7KiKBuiT1M28CFhCqW98SAjpcuZZnxqRL9XGME%3D&amp;TOPIC_ID=1434" target="_blank">Alpha-1 Foundation</a>). Information about clinical trials for patients with AAT deficiency, including many of the emerging therapies discussed above, is available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=1434" target="_blank">ClinicalTrials.gov</a> and at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrialsregister.eu%2Fctr-search%2Fsearch%3Bjsessionid%3Ds4R1ThtXzSQTm4b2D2v7fmbtXcTl2WntWR1QxXm2JRqNTRJ1DS3c%21-1664628246&amp;token=loH3jX2OK%2B1%2FjUPccT9uP4VDsKB0%2Fb0TyHtwsvnYSBgAcB4iFOmdnOUl1Mbq1%2BA9FCBpAmvYcS3FpW868PUHf6jCQmuqK7kQU6no556Ri61tb8EHngVzqprUakaRC0kLqVrDpSGRAjQeAkakUt9LWWd%2FtfYpWo2qMXXtWyZYwj6vALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=1434" target="_blank">EU Clinical Trials Register</a>.</p><p class="headingAnchor" id="H3032279854"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110267.html" rel="external">"Society guideline links: Chronic obstructive pulmonary disease"</a>.)</p><p class="headingAnchor" id="H1859655"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Severe deficiency of alpha-1 antitrypsin (AAT) due to certain genetic variants  (<a class="graphic graphic_table graphicRef57264" href="/d/graphic/57264.html" rel="external">table 2</a>) is associated with both early onset pulmonary emphysema and several forms of liver disease, including cirrhosis, neonatal hepatitis, and hepatocellular carcinoma. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/d/html/1464.html" rel="external">"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency"</a> and  <a class="medical medical_review" href="/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe deficiency of AAT is defined as a low serum level of AAT (ie, &lt;11 micromol/L or &lt;57 mg/dL by immunodiffusion) due to a genetic variant  (<a class="graphic graphic_algorithm graphicRef104220" href="/d/graphic/104220.html" rel="external">algorithm 2</a>). (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/d/html/1464.html" rel="external">"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency", section on 'Evaluation and diagnosis'</a>.).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All individuals with genetic variants of AAT should be advised to avoid active or passive cigarette smoke exposure to reduce the risk of developing emphysema. (See <a class="local">'Supportive care and standard medical therapy'</a> above and  <a class="medical medical_patient" href="/d/html/2729.html" rel="external">"Patient education: Quitting smoking (Beyond the Basics)"</a> and  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supportive therapy for patients with emphysema due to AAT deficiency follows the usual guidelines for COPD and includes pulmonary rehabilitation, nutritional support, supplemental oxygen, preventive vaccination (eg, influenza and pneumococcal vaccines), and prompt treatment of lower respiratory tract infections. (See <a class="local">'Supportive care and standard medical therapy'</a> above and  <a class="medical medical_review" href="/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical therapy with bronchodilators (eg, beta agonists and muscarinic antagonists) and inhaled or oral glucocorticoids should follow guidelines for COPD. (See <a class="local">'Supportive care and standard medical therapy'</a> above and  <a class="medical medical_review" href="/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For AAT deficient patients who are never or ex-smokers, age 18 or older with an AAT genetic variant consistent with severe AAT deficiency, and evidence of airflow limitation (forced expiratory volume in one second [FEV<sub>1</sub>] 30 to 65 percent predicted), we suggest intravenous augmentation with pooled human AAT  (<a class="graphic graphic_algorithm graphicRef112788" href="/d/graphic/112788.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Indications for use of AAT augmentation outside these thresholds for airflow limitation have not been uniformly agreed upon. (See <a class="local">'Patient selection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the majority of patients receiving AAT augmentation, pooled human AAT is administered intravenously 60 mg/kg actual body weight, per week. The rate of infusion depends on the specific preparation  (<a class="graphic graphic_table graphicRef52673" href="/d/graphic/52673.html" rel="external">table 1</a>). (See <a class="local">'Infusion'</a> above and <a class="local">'Formulations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pooled human plasma AAT contains small amounts of IgA. Rare systemic anaphylactic reactions to pooled human plasma AAT have been reported, possibly due to antibodies to IgA in IgA deficient individuals. (See <a class="local">'Pretreatment preparation'</a> above and <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The experience with lung volume reduction surgery (LVRS) for patients with AAT deficiency is limited, but thus far LVRS has not been shown to improve survival or substantially improve lung function compared with medical therapy. (See <a class="local">'Lung volume reduction surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung transplantation is reserved for patients with advanced emphysema due to severe AAT deficiency. Similarly, liver transplantation is reserved for patients with end-stage hepatic disease. After liver transplantation, the AAT deficiency is corrected, because the normal phenotype donor liver produces and secretes AAT. (See <a class="local">'Lung and liver transplantation'</a> above.)</p><p></p><p class="headingAnchor" id="H6009992"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Marc Rovner, MD, FACP, FCCP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hubbard RC, Crystal RG. Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency. Am J Med 1988; 84:52.</a></li><li><a class="nounderline abstract_t">Hubbard RC, Crystal RG. Augmentation therapy of alpha 1-antitrypsin deficiency. Eur Respir J Suppl 1990; 9:44s.</a></li><li class="breakAll">Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org (Accessed on November 16, 2023).</li><li><a class="nounderline abstract_t">McElvaney GN, Sandhaus RA, Miravitlles M, et al. Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Stoller JK, Aboussouan LS, Kanner RE, et al. Characteristics of Alpha-1 Antitrypsin-Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2015; 12:1796.</a></li><li><a class="nounderline abstract_t">Stoller JK, Aboussouan LS. alpha1-Antitrypsin deficiency . 5: intravenous augmentation therapy: current understanding. Thorax 2004; 59:708.</a></li><li><a class="nounderline abstract_t">Sandhaus RA. alpha1-Antitrypsin deficiency . 6: new and emerging treatments for alpha1-antitrypsin deficiency. Thorax 2004; 59:904.</a></li><li><a class="nounderline abstract_t">American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168:818.</a></li><li><a class="nounderline abstract_t">Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Can Respir J 2012; 19:109.</a></li><li><a class="nounderline abstract_t">Attaway A, Majumdar U, Sandhaus RA, et al. An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2019; 14:2089.</a></li><li><a class="nounderline abstract_t">Sandhaus RA, Turino G, Brantly ML, et al.. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chron Obstru Pulm Dis (Miami) 2016; 3:668.</a></li><li><a class="nounderline abstract_t">Sandhaus RA, Turino G, Stocks J, et al. alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note. Chest 2008; 134:831.</a></li><li><a class="nounderline abstract_t">Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316:1055.</a></li><li><a class="nounderline abstract_t">Barker AF, Iwata-Morgan I, Oveson L, Roussel R. Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency. Chest 1997; 112:607.</a></li><li><a class="nounderline abstract_t">Hubbard RC, Sellers S, Czerski D, et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA 1988; 260:1259.</a></li><li><a class="nounderline abstract_t">Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency. Eur Respir J 2017; 50.</a></li><li><a class="nounderline abstract_t">Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33:1345.</a></li><li><a class="nounderline abstract_t">Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158:49.</a></li><li><a class="nounderline abstract_t">Wencker M, Banik N, Buhl R, et al. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J 1998; 11:428.</a></li><li><a class="nounderline abstract_t">Stoller JK, Aboussouan LS. A review of α1-antitrypsin deficiency. Am J Respir Crit Care Med 2012; 185:246.</a></li><li><a class="nounderline abstract_t">Chapman KR, Burdon JG, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386:360.</a></li><li><a class="nounderline abstract_t">Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981; 68:1158.</a></li><li><a class="nounderline abstract_t">Stoller JK, Fallat R, Schluchter MD, et al. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest 2003; 123:1425.</a></li><li><a class="nounderline abstract_t">Meyer FJ, Wencker M, Teschler H, et al. Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor. Eur Respir J 1998; 12:996.</a></li><li class="breakAll">Baxter, Miles Recall Blood, Plasma Products After Donor Dies. Chicago Tribune, 1994. http://articles.chicagotribune.com/1994-11-23/business/9411230190_1_plasma-products-creutzfeldt-jakob-disease-virus-like-agent (Accessed on March 02, 2017).</li><li class="breakAll">US Food and Drug Administration. Alpha1-proteinase inhibitor (Human): Prolastin-C. http://www.fda.gov/downloads/biologicsbloodvaccines/ucm209676... (Accessed on February 03, 2017).</li><li class="breakAll">US Food and Drug Administration. Alpha1-proteinase inhibitor (Human): Aralast http://www.fda.gov/downloads/BloodBloodProducts/ucm092856.pdf (Accessed on February 03, 2017).</li><li class="breakAll">US Food and Drug Administration. Alpha1-proteinase inhibitor (Human): Glassia. http://www.fda.gov/downloads/ApprovedProducts/UCM217890.pdf (Accessed on February 03, 2017).</li><li class="breakAll">US Food and Drug Administration. Alpha1-proteinase inhibitor (Human): Zemaira. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM172304.pdf (Accessed on February 03, 2017).</li><li><a class="nounderline abstract_t">Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160:1468.</a></li><li><a class="nounderline abstract_t">Chapman KR, Stockley RA, Dawkins C, et al. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD 2009; 6:177.</a></li><li><a class="nounderline abstract_t">Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev 2010; :CD007851.</a></li><li><a class="nounderline abstract_t">Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev 2016; 9:CD007851.</a></li><li><a class="nounderline abstract_t">McElvaney NG, Burdon J, Holmes M, et al. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med 2017; 5:51.</a></li><li><a class="nounderline abstract_t">Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118:1480.</a></li><li><a class="nounderline abstract_t">Barros-Tizón JC, Torres ML, Blanco I, et al. Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy. Ther Adv Respir Dis 2012; 6:67.</a></li><li><a class="nounderline abstract_t">A registry of patients with severe deficiency of alpha 1-antitrypsin. Design and methods. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1994; 106:1223.</a></li><li><a class="nounderline abstract_t">Fraughen DD, Ghosh AJ, Hobbs BD, et al. Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis. Am J Respir Crit Care Med 2023; 208:964.</a></li><li><a class="nounderline abstract_t">Seersholm N, Wencker M, Banik N, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997; 10:2260.</a></li><li><a class="nounderline abstract_t">Wencker M, Fuhrmann B, Banik N, et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001; 119:737.</a></li><li><a class="nounderline abstract_t">Stoller JK. The Challenge of Rare Diseases. Chest 2018; 153:1309.</a></li><li><a class="nounderline abstract_t">Stoller JK, Gildea TR, Ries AL, et al. Lung volume reduction surgery in patients with emphysema and alpha-1 antitrypsin deficiency. Ann Thorac Surg 2007; 83:241.</a></li><li><a class="nounderline abstract_t">Dauriat G, Mal H, Jebrak G, et al. Functional results of unilateral lung volume reduction surgery in alpha1-antitrypsin deficient patients. Int J Chron Obstruct Pulmon Dis 2006; 1:201.</a></li><li><a class="nounderline abstract_t">Tejwani V, Wang XF, Stoller JK. The Natural History of Lung Function in Severe Deficiency of Alpha-1 Antitrypsin Following Orthotopic Liver Transplantation: A Case Report. Chronic Obstr Pulm Dis 2015; 2:290.</a></li><li><a class="nounderline abstract_t">Carey EJ, Iyer VN, Nelson DR, et al. Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency–related cirrhosis. Liver Transpl 2013; 19:1370.</a></li><li><a class="nounderline abstract_t">Jain AB, Patil V, Sheikh B, et al. Effect of liver transplant on pulmonary functions in adult patients with alpha 1 antitrypsin deficiency: 7 cases. Exp Clin Transplant 2010; 8:4.</a></li><li><a class="nounderline abstract_t">Morer L, Choudat L, Dauriat G, et al. Liver Involvement in Patients With PiZZ-Emphysema, Candidates for Lung Transplantation. Am J Transplant 2017; 17:1389.</a></li><li><a class="nounderline abstract_t">Banga A, Gildea T, Rajeswaran J, et al. The natural history of lung function after lung transplantation for α(1)-antitrypsin deficiency. Am J Respir Crit Care Med 2014; 190:274.</a></li><li><a class="nounderline abstract_t">Tanash HA, Riise GC, Hansson L, et al. Survival benefit of lung transplantation in individuals with severe α1-anti-trypsin deficiency (PiZZ) and emphysema. J Heart Lung Transplant 2011; 30:1342.</a></li><li><a class="nounderline abstract_t">Caughey GH. Should alpha 1-antitrypsin-deficient patients with emphysema continue to receive alpha 1-antitrypsin after lung transplantation? J Heart Lung Transplant 1993; 12:708.</a></li><li><a class="nounderline abstract_t">Strange C, Stoller JK, Sandhaus RA, et al. Results of a survey of patients with alpha-1 antitrypsin deficiency. Respiration 2006; 73:185.</a></li><li><a class="nounderline abstract_t">Teschler H. Long-term experience in the treatment of α1-antitrypsin deficiency: 25 years of augmentation therapy. Eur Respir Rev 2015; 24:46.</a></li><li><a class="nounderline abstract_t">King MB, Campbell EJ, Gray BH, Hertz MI. The proteinase-antiproteinase balance in alpha-1-proteinase inhibitor-deficient lung transplant recipients. Am J Respir Crit Care Med 1994; 149:966.</a></li></ol></div><div id="topicVersionRevision">Topic 1434 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3289387" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2340051" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Augmentation therapy of alpha 1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2340051" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Augmentation therapy of alpha 1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32165400" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical considerations in individuals withα1-antitrypsin PI*SZ genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26653189" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Characteristics of Alpha-1 Antitrypsin-Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15282394" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : alpha1-Antitrypsin deficiency . 5: intravenous augmentation therapy: current understanding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15454659" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : alpha1-Antitrypsin deficiency . 6: new and emerging treatments for alpha1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14522813" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22536580" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31564856" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The diagnosis and management of alpha-1 antitrypsin deficiency in the adult</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18842915" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3494198" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9315791" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3261353" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29191952" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : European Respiratory Society statement: diagnosis and treatment of pulmonary disease inα1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19196813" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9655706" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9551749" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21960536" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A review ofα1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26026936" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Intravenous augmentation treatment and lung density in severeα1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7028785" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12740257" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817182" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817182" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817182" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817182" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817182" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817182" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10556107" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19811373" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20614465" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27644166" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27916480" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term efficacy and safety ofα1 proteinase inhibitor treatment for emphysema caused by severeα1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083705" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22354900" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7924498" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A registry of patients with severe deficiency of alpha 1-antitrypsin. Design and methods. The Alpha 1-Antitrypsin Deficiency Registry Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37624745" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9387950" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11243951" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29325986" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The Challenge of Rare Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17184672" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Lung volume reduction surgery in patients with emphysema and alpha-1 antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18046897" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Functional results of unilateral lung volume reduction surgery in alpha1-antitrypsin deficient patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28848851" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Natural History of Lung Function in Severe Deficiency of Alpha-1 Antitrypsin Following Orthotopic Liver Transplantation: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24019185" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency–related cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20199364" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of liver transplant on pulmonary functions in adult patients with alpha 1 antitrypsin deficiency: 7 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27931086" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Liver Involvement in Patients With PiZZ-Emphysema, Candidates for Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25003824" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The natural history of lung function after lung transplantation forα(1)-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21821433" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Survival benefit of lung transplantation in individuals with severeα1-anti-trypsin deficiency (PiZZ) and emphysema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8369332" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Should alpha 1-antitrypsin-deficient patients with emphysema continue to receive alpha 1-antitrypsin after lung transplantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16141711" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Results of a survey of patients with alpha-1 antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25726554" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Long-term experience in the treatment ofα1-antitrypsin deficiency: 25 years of augmentation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8143063" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The proteinase-antiproteinase balance in alpha-1-proteinase inhibitor-deficient lung transplant recipients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
